SCHEMBL31140543

SCHEMBL31140543

Fc1cc(Cl)ccc1CN1CCOc2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.47
▸ HTR1A P08908 1/20 0.47
▸ HTR2A P28223 1/20 0.47
▸ HTR7 P34969 1/20 0.47
▸ HTR6 P50406 1/20 0.47
▸ TSHR P16473 4/20 0.46
▸ POLB P06746 2/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ GRM5 P41594 1/20 0.42
▸ DRD2 P14416 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ P2RX7 Q99572 2/20 0.41
▸ CXCR3 P49682 2/20 0.41
▸ HDAC1 Q13547 2/20 0.40
▸ HDAC6 Q9UBN7 2/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ GRM2 Q14416 1/20 0.40
▸ SIRT2 Q8IXJ6 1/20 0.39
▸ SIRT1 Q96EB6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8553080 0.87 CYP2A13 (0.50) TSHRPOLBKMT2ADRD2DRD4
SCHEMBL12108587 0.78 HDAC1 (0.40) TP53HTR1AHTR2AHTR7HTR6
SCHEMBL22391824 0.75 GRM2 (0.43) TP53HTR1AHTR2AHTR7HTR6
SCHEMBL9147970 0.74 TSHR (0.58) HTR1ATSHRKMT2AGRM5HPGD
SCHEMBL28892515 0.72 POLB (0.52) HTR1ATSHRPOLBKMT2AGRM5
SCHEMBL30002695 0.72 POLB (0.52) HTR1ATSHRPOLBKMT2AGRM5
SCHEMBL18783813 0.71 PTGIR (0.43) —
SCHEMBL22391952 0.70 HTR3A (0.45) TP53HTR1AHTR2AHTR7HTR6
SCHEMBL28238549 0.70 HDAC1 (0.56) HTR1ATSHRPOLBKMT2AGRM5
SCHEMBL2208731 0.70 HDAC1 (0.53) HTR1ATSHRPOLBKMT2AGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568664-A1 COMBINATION COMPRISING A THR-BETA AGONIST AND A GLP-1R AGONIST FOR USE IN TREATING A LIVER DISORDER OR A CARDIOMETABOLIC DISEASE Terns Pharmaceuticals, Inc. (US) 2025-06-18 — — EP disclosed
WO-2024211898-A1 COMBINATION COMPRISING A THRBETA AGONIST ANDA GLP-1R AGONIST FOR USE IN TREATING A LIVER DISORDER OR A CARDIOMETABOLIC DISEASE TERNS PHARMACEUTICALS, INC. (US) 2024-10-10 — — WO disclosed
Send feedback